Abdel Chahbouni
VU University Medical Center
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Abdel Chahbouni.
Journal of Chromatography B | 2009
Abraham J. Wilhelm; J.C.G. den Burger; René M. Vos; Abdel Chahbouni; Arno Sinjewel
Dried blood spot sampling is a promising and patient friendly alternative for venous sampling. A liquid chromatography tandem mass spectrometer assay was developed for analyzing cyclosporin A in dried blood spots. Linearity ranged from 25 to 1440 microg/L. Within and between run accuracy and precision were within limits. The developed assay has a negligible matrix-effect and a recovery of 97%. The dried blood spots were stable during a period of at least 17 days in the refrigerator. The developed assay is suitable for analyzing cyclosporin A in dried blood spots.
Therapeutic Drug Monitoring | 2009
Abdel Chahbouni; J. C. G. Den Burger; René M. Vos; Arno Sinjewel; Abraham J. Wilhelm
A quantitative liquid chromatography (LC)-mass spectrometry (MS)/MS method in human plasma was developed and validated for the tyrosine kinase inhibitors erlotinib, gefitinib, and imatinib in human plasma. Pre-treatment of the samples was achieved by using liquid-liquid extraction using D-8 imatinib as internal standard. Separation was performed on a Waters Alliance 2795 LC system using an XBridge RP18 column. The mass spectrometer Micromass was equipped with an electro spray ionization probe, operating in the positive mode. The calibration curves in plasma were linear for erlotinib, gefitinib, and imatinib over the concentration range of 5 to 3,000; 5 to 3,000, and 5 to 5,000 ng/mL, respectively. The intraday and interday accuracy ranged from 90% to 110% and the intraday and interday precision of the method was within 5%. The reported method provided the necessary linearity, precision, and accuracy to determine tyrosine kinase inhibitors in clinical research and for therapeutic drug monitoring.
Journal of Chromatography B | 2009
Abraham J. Wilhelm; J.C.G. den Burger; Abdel Chahbouni; René M. Vos; Arno Sinjewel
At our laboratory a reversed phase high performance liquid chromatography assay was developed for analysis of mycophenolic acid in dried blood spot samples. The assay was validated in the range of 0.74-23.4mg/L and proved to be accurate and precise. The developed sample pretreatment procedure was consistent and has a recovery of 95.2% for mycophenolic acid. Hematocrit showed to have influence on the physics of the blood spots and thus on the concentration of mycophenolic acid, therefore standard and control samples should be made with a standardized hematocrit.
Journal of Chromatography B | 2008
René M. Vos; Abdel Chahbouni; Arno Sinjewel; Eleonora L. Swart
A simple, sensitive and specific liquid chromatography tandem mass spectrometry method with minimal sample pretreatment was developed for the simultaneous analysis of sildenafil and its metabolite desmethylsildenafil in human serum. Sample pretreatment consisted of adding a methanolic solution of the internal standard vardenafil to the samples. After vortexing and centrifugation the samples were directly injected onto the C18 column using gradient elution. The aqueous and organic mobile phases were ammonium acetate 2 mM supplemented with 0.1% formic acid in water and methanol, respectively. The detection by a triple quadrupole mass spectrometer in positive ESI ionization mode was completed within 5 min. The lower limits of quantification for sildenafil and desmethylsildenafil are 1.0 ng/ml. The intra- and inter-day precisions measured as relative standard deviation were within 10% for both compounds over the linear range. Intra- and inter-day accuracy of sildenafil and desmethylsildenafil ranged from 92 to 103%. This method has been used in a clinical pharmacokinetic study of sildenafil in intensive care patients.
Analytical and Bioanalytical Chemistry | 2015
Jeroen C. G. den Burger; Aabraham J. Wilhelm; Abdel Chahbouni; René M. Vos; Arno Sinjewel; Eleonora L. Swart
We developed a method for the analysis of creatinine in dried blood spot (DBS) samples to facilitate monitoring of renal function in combination with TDM of immunosuppressive drugs for transplant patients outside the hospital. An 8-mm disc of the DBS was punched, extracted and followed by LC–MS/MS analysis. The haematocrit proved to have a significant influence on the analysis of creatinine in DBS samples. As potassium is a suitable marker for haematocrit, we implemented a method for measuring potassium in DBS and correct the creatinine for haematocrit. For both creatinine and K+ in DBS analytical and DBS, validation was performed, both components met the validation criteria and no other influences beside the haematocrit were detected. To assess the haematocrit correction, samples were compared to the ‘golden’ standard and plotted before and after correction. The correction showed a great improvement in agreement between the DBS assay and venous blood assay.
Therapeutic Drug Monitoring | 2013
Abdel Chahbouni; Arno Sinjewel; Jeroen C. G. den Burger; René M. Vos; Abraham J. Wilhelm; Agnes I. Veldkamp; Eleanora L. Swart
Background:Gabapentin (GBP), pregabalin (PRG), and vigabatrin (VIG) are used for the prevention and treatment of epileptic seizures. The developed method was applied to samples from subjects participating in a pharmacokinetic study of GBP. Methods:Sample pretreatment consisted of adding 20 &mgr;L of trichloroacetic acid (30%; vol/vol) and 200 &mgr;L of GBP-d4 in acetonitrile as an internal standard to 20 &mgr;L of serum. Chromatographic separation was performed on an Acquity separation module using a Kinetex RP18 column. The aqueous and organic mobile phases were 2 mM ammonium acetate supplemented with 0.1% formic acid in water and acetonitrile, respectively. The detection by a tandem quadrupole mass spectrometer, operating in the positive mode using multiple reaction monitoring, was completed within 2 minutes. Results:The method was linear over the range of 0.03–25 mg/L for GBP, 0.03–25 mg/L for PRG, and 0.06–50 mg/L for VIG. The between- and within-run accuracies ranged from 90% to 107%. The between- and within-run imprecisions of the method were <10%. Stability data show no significant decrease of the analytes. A relative matrix effect of −1%, 0.2%, and −5% was determined for GBP, PRG, and VIG, respectively. Conclusions:A simple and sensitive ultraperformance liquid chromatography–tandem mass spectrometry method was developed and validated for the simultaneous quantification of GBP, PRG, and VIG in human serum. The reported method provided the necessary linearity, precision, and accuracy to allow the determination of GBP, PRG, and VIG for therapeutic drug monitoring and clinical research purposes.
Therapeutic Drug Monitoring | 2010
Abdel Chahbouni; Abraham J. Wilhelm; Jeroen C. G. den Burger; Arno Sinjewel; René M. Vos
A liquid chromatography-tandem mass spectrometry method was developed and validated for the simultaneous quantification of voriconazole, fluconazole, posaconazole, itraconazole, and hydroxyitraconazole in human serum. A simple protein precipitation was used as sample pretreatment with ketoconazole as the internal standard. Chromatographic separation was performed on a Waters Alliance 2795 liquid chromatography system using a XBridge RP18 column. The mass spectrometer from Micromass was equipped with an electrospray ionization probe operating in the positive mode using multiple reaction monitoring. The method was linear over the range of 0.01 to 5.00 mg/L for itraconazole, 0.01 to 5.00 mg/L for OH-itraconazole, 0.02 to 10.00 mg/L for voriconazole, 0.06 to 30.00 mg/L for fluconazol, and 0.02 to 10.00 mg/L for posaconazole. The between- and within-run accuracy ranged from 92% to 110%. The between- and within-run imprecision of the method was less than 11%. The reported method provided the necessary linearity, precision, and accuracy to allow the determination of four antimycotic agents for therapeutic drug monitoring and pharmacokinetic-pharmacodynamic studies.
Clinical Toxicology | 2017
Marieke Jantien Henstra; Liza Wong; Abdel Chahbouni; Noortje Swart; Cor Allaart; Ferdi Sombogaard
Abstract Background: Ibogaine is an agent that has been evaluated as an unapproved anti-addictive agent for the management of drug dependence. Sudden cardiac death has been described to occur secondary to its use. We describe the clinical effects and toxicokinetics of ibogaine and noribogaine in a single patient. For this purpose, we developed a LC-MS/MS-method to measure ibogaine and noribogaine plasma-concentrations. We used two compartments with first order absorption. Case details: The maximum concentration of ibogaine was 1.45 mg/L. Our patient developed markedly prolonged QTc interval of 647ms maximum, several multiple cardiac arrhythmias (i.e., atrial tachycardia and ventricular tachycardia and Torsades des Pointes). QTc-prolongation remained present until 12 days after ingestion, several days after ibogaine plasma-levels were low, implicating clinically relevant noribogaine concentrations long after ibogaine had been cleared from the plasma. The ratio k12/k21 for noribogaine was 21.5 and 4.28 for ibogaine, implicating a lower distribution of noribogaine from the peripheral compartment into the central compartment compared to ibogaine. Conclusions: We demonstrated a linear relationship between the concentration of the metabolite and long duration of action, rather than with parent ibogaine. Therefore, after (prolonged) ibogaine ingestion, clinicians should beware of long-term effects due to its metabolite.
Journal of Pharmacy and Pharmacology | 2017
Christel C. L. M. Boons; Abdel Chahbouni; Anneliene M. Schimmel; Abraham J. Wilhelm; Yvonne den Hartog; Jeroen J.W.M. Janssen; N. Harry Hendrikse; Jacqueline G. Hugtenburg; Eleonora L. Swart
To compare nilotinib concentrations obtained by venous blood sampling and dried blood spot (DBS) in patients with chronic myeloid leukaemia (CML). It was investigated how to predict nilotinib plasma levels on the basis of DBS.
Bioanalysis | 2015
Abdel Chahbouni; Frank A. M. van den Dungen; René M. Vos; Jeroen C. G. den Burger; Amo Sinjewel; Abraham J. Wilhelm; Agnes I. Veldkamp; Eleanor L Swart; Mirjam M. van Weissenbruch
BACKGROUND An UPLC-MS detection method for the quantification of amikacin, flucloxacillin, meropenem, penicillin G and vancomycin was developed and validated. RESULTS The calibration curves were found to be linear from 0.47 to 50 mg/l for amikacin, 1.28 to 135 mg/l for flucloxacillin, 0.75 to 80 mg/l for meropenem, 0.38 to 80 mg/l for penicillin G and 0.73 to 80 mg/l for vancomycin. Between- and within-run accuracy was ranged between 85 and 115%. Between and within imprecision expressed as CV was within 15%. CONCLUSION The validated method was successfully applied to a PK study in very preterm and small for gestational age infants treated for nosocomial sepsis and/or meningitis.